Kallyope Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 83
Employees
  • Latest Deal Type
  • Series D
  • Latest Deal Amount
  • $236M
Latest Deal Amount
  • Investors
  • 19

Kallyope General Information

Description

Operator of a biotechnology company intended to explore the therapeutic potential of gut-brain circuits. The company's platform integrates technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology, enabling healthcare industries to develop improved therapeutics for human health and nutrition.

Contact Information

Website
www.kallyope.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 430 East 29th Street
  • 10th Floor
  • New York, NY 10016
  • United States
+1 (646) 000-0000

Kallyope Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Kallyope Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series D) 15-Feb-2022 $236M 00000 00.000 Completed Generating Revenue
3. Later Stage VC (Series C) 25-Mar-2020 00000 00000 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 05-Dec-2018 $87M $131M 00000 Completed Generating Revenue
1. Early Stage VC (Series A) 10-Dec-2015 $44M $44M 0000 Completed Generating Revenue
To view Kallyope’s complete valuation and funding history, request access »

Kallyope Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series D 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series C 00,000,000 00.000000 00 00 00 00 00 00.000
Series B 43,454,779 $0.001000 8% $2 $2 1x $2 20.85%
Series A 44,050,000 $0.001000 8% $1 $1 1x $1 21.13%
To view Kallyope’s complete cap table history, request access »

Kallyope Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a biotechnology company intended to explore the therapeutic potential of gut-brain circuits. The company's p
Drug Discovery
New York, NY
83 As of 2022
00000
0.000 0000-00-00
00000000000 00000

000000 0

or in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint o
0000 000000000
Brisbane, CA
00 As of 0000
000.00
00000000000 000.00

0000000

dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore m
0000000000000
Waltham, MA
0 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kallyope Competitors (30)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Second Genome Venture Capital-Backed Brisbane, CA 00 000.00 00000000000 000.00
0000000 0000000000 Formerly VC-backed Waltham, MA 0 00000 000000000 00000
00000 000000000000 Formerly VC-backed Cambridge, MA 000 00000 000000000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
00000 000000000000 Venture Capital-Backed Woburn, MA 00 00000 00000000000 00000
You’re viewing 5 of 30 competitors. Get the full list »

Kallyope Executive Team (13)

Name Title Board Seat Contact Info
James Galeota Jr. Chief Executive Officer, President & Board Member
Nancy Thornberry Chairman, Research & Development & Founding CEO
Patrick Flanigan III Chief Financial Officer
Juha Lauren Ph.D Chief Business Officer
Alexander Rives Co-Founder
You’re viewing 5 of 13 executive team members. Get the full list »

Kallyope Board Members (9)

Name Representing Role Since
Adam Goulburn Ph.D Lux Capital Board Member 000 0000
Amy Schulman JD Polaris Partners Board Member 000 0000
Joshua Wolfe Lux Capital Strategic Advisor & Board Member 000 0000
Nancy Thornberry Kallyope Chairman, Research & Development & Founding CEO 000 0000
Peter Hecht Ph.D Self Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Kallyope Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kallyope Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Bill Gates Angel (individual) Minority 000 0000 000000 0
DNS Capital Family Office Minority 000 0000 000000 0
Hartford Healthcare Endowment Other Minority 000 0000 000000 0
Mubadala Investment Company Sovereign Wealth Fund Minority 000 0000 000000 0
Parkwood Family Office Minority 000 0000 000000 0
You’re viewing 5 of 19 investors. Get the full list »

Ready to get started?

Request a free trial